ABT-100 is primarily used in the field of oncology research as a potential therapeutic agent. It functions as a farnesyltransferase inhibitor, targeting the Ras signaling pathway, which is often implicated in various cancers. By inhibiting this pathway, ABT-100 aims to halt the proliferation of cancer cells and induce apoptosis. Its application is particularly significant in studies focusing on cancers driven by Ras mutations, such as pancreatic, lung, and colorectal cancers. Researchers are exploring its efficacy in preclinical and clinical trials to determine its potential as a targeted cancer therapy. Additionally, ABT-100 is being investigated for its ability to enhance the effectiveness of other chemotherapy drugs when used in combination treatments.